Background: Vascular endothelial growth factor (VEGF) plays a role in the development of cancer and the progression of liquid tumors such as chronic lymphatic leukemia, non-Hodgkin lymphomas, and multiple myeloma. VEGF also triggers endothelial cells to secrete hematopoietic growth factors such as interleukin-6 (IL-6); this in turn promotes further leukemia growth, thereby contributing to a paracrine loop between the leukemia and the endothelial cells. Methods: We transfected a small interfering RNA (siRNA) targeting VEGF into K562 cells in order to investigate the role of VEGF in the development of leukemic cancer. After the conditioned media (CM) of the K562 was cells added to the human umbilical endothelial cell (HUVEC) culture media, we compared the proliferation and tube formation of the HUVECs. Recombinant human prothrombin kringle2 (K2), which is a known angiogenic inhibitor, was also treated onto the HUVECs, and we then examined the level of IL-6 to determine the paracrine interaction between the leukemic and endothelial cells. Results: RT-PCR and western blot analysis demonstrated that the siRNA efficiently down regulated the expression of VEGF in the K562 cells. When the CM of the K562 cells was added to the HUVEC culture, the proliferation of the HUVECs was stimulated. The proliferation of the HUVEC induced by the CM from the siRNA-VEGF K562 cells was diminished, compared with that of the vector control K562 cells. K2 reduced not only the proliferation of the HUVECs, but also the secretion of IL-6 by the HUVEC. Conclusion: The siRNA strategy is an alternative tool for inhibiting leukemia-induced angiogenesis. A combinated therapy with angiogenesis inhibitor K2 increases the efficiency. K2 modulates the production of IL-6, which may affect the paracrine interaction between leukemia and endothelial cells. (Korean J  Hematol 2005;40:211-218.) 
INTRODUCTION
VEGF is a cytokine essential for the vasculogenesis associated with normal embryonic development and for the angiogenesis associated with wound healing, cancers, and a variety of other important pathologies. 1) It is well recognized that VEGF promotes tumor angiogenesis and that secretion of bioactive VEGF by cancer cells may be directly involved in tumor progression. 2) There are increasing evidences indicating that VEGF plays a role in cancer development and progression not only in solid tumors but also in liquid tumors such as chronic lymphatic leukemia, non-Hodgkin lymphomas, and multiple myeloma.
3)
A number of reports have demonstrated that modulating the expression of VEGF in tumor cells resulted in either stimulation or inhibition of tumor angiogenesis and tumor growth. Schuch et al. showed that delivery of VEGF using microencapsulation technology enhanced tumor growth and vascularization, whereas treatment with a VEGF antagonist soluble NRP-1 inhibited tumor angiogenesis and growth. 4) The expression of VEGF in tumor xenografts in nude mice has been shown to stimulate tumor growth and tumor angiogenesis. 5) Down-regulated VEGF protein expression by antisense RNA in colon cancer cells resulted in inhibition of endothelial cell proliferation in tumor angiogenesis in vivo. 6) Similarly, transfection of antisense VEGF effectively down-regulated VEGF secretion from head and neck squamous cell carcinoma cells and also inhibited the in vivo tumorigenicity of brain tumor cells. 7, 8) VEGF also exert effects on cells in a manner unrelated to its angiogenic activity. VEGF induced both a time-and dose-dependent increase in IL-6 production from microvascular endothelial cells. 9) Since IL-6 act as a survival factor for myeloma cells by preventing tumor cell apoptosis, it is conceivable that endothelial cells may, in response to VEGF, release cytokines capable of sustaining tumor growth through paracrine loop.
In this report, we demonstrate that downregulation of VEGF expression in leukemic cell line K562 cells using siRNA inhibits tumor angiogenesis. We also show that VEGF, secreted in CM of K562 cells, promotes the production of IL-6 by HUVEC. Since K2, reported as an angiogenesis inhibitor, 10, 11) reduces the secretion of IL-6 by HUVEC, K2 may play a role in the paracrine interaction between leukemia and endothelial cells.
MATERIALS AND METHODS

Cell culture
K562 was cultured in RPMI-1640 with 10% fetal bovine serum (FBS), penicillin (100U/mL), and streptomycin (100ug/mL). HUVEC was grown in EBM-2 medium (Clonetics, Walkersville, MD, USA) with 10ng/mL epidermal growth factor, 1ug/mL hydrocortisone, 10ug/mL bovine brain extract, 2% fetal bovine serum (FBS), 50ug/ mL gentamicin and 50ng/mL Amphotericin B.
siRNA
We designed and synthesized complementary oligonucleotides against VEGF mRNA with 5' single strand overhangs for ligation into the pSilencer TM 1.0-U6 (Ambion, Austin, TX, USA) vector (5'-gatcccAAATGTGAATGCAGACCAAA GttcaagagaCTTTGGTCTGCATTCACATTTtttttt ggaaa-3'; 3'-agcttttccaaaaaaAAATGTGAATGCAG ACCAAAGtctcttgaaCTTTGGTCTGCATTCACA TTTgg-5'). In vitro transfection was performed using LipofectAMINE PLUS (Invitogen, Carlsbad, CA, USA) according to the manufacturers instructions. HUVECs were plated at a density of 8×10 4 cells per well in 24-well plates. After 20h and 70～80% confluence, the cells were transfected with siRNAs in serum-free medium using LipofectAMINE PLUS. 0.8μg of siRNA was diluted with Opti-MEM (50μL) in a small sterile tube. After immediate mixing, the Lipofect-AMINE reagent (2μL) in Opti-MEM (50μL) was added, and the mixture was left at room temperature for 20 min. The HUVEC culture medium was replaced by fresh medium and the siRNAlipid complex (100uL) was added. After incubation for 4h at 37°C, 1mL of EBM-2 medium with 10% FBS was added. After 1 day, culture media changed to selective media containing 500U/mL of hygromycin to select cells containing the siRNA-VEGF vector.
Semiquantitative Reverse Transcription-PCR Analysis for VEGF Gene Expression
Total RNA was obtained from cells using Trizol reagent (Invitorgen, Carlsbad, CA, USA). Reverse transcription-PCR was performed with the isolated total RNA (1ug) using Access RT-PCR system (Promega, Madison, MI, USA) according to the manufacturers instructions. The following primer pairs were used. Sense 5'-CCCT GATGAGATCGAGTACATCTT-3' and antiense 5'-GCCTCGGCTTGTCACATTTT-3'.
Conditioned medium (CM)
1.5×10 6 K562 cells were cultured in serum-free RPMI-1640. After 72h, the culture supernatants were collected and cell debris was removed by centrifugation at 15,000×g for 5min at 4 o C.
Western blotting
CM of K562 cells were concentrated using Centricon YM-10 (Millipore, Billerica, MA, USA). Protein samples were separated by SDS-PAGE, transferred onto nitrocellulose membrane. After blocking, membrane was incubated with anti-EGF antibody. Bound antibodies were detected using peroxidase-coupled secondary antibodies, followed by developing using ECL plus (Amersham, Uppsala, Sweden).
Recombinant prothrombin kringle 2 (K2)
K2 was expressed and purified according to the protocol previously established in our laboratory. 10, 11) 
Endothelial cell proliferation assays
HUVECs (5×10 3 /well) were plated in 96 well plates in RPMI-1640 with 50% (v/v) CM. After 72h, 50uL of a 2mg/mL solution of MTT [3-(4,5imethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide] was added to the wells and incubated at 37 o C for 3h. The supernatant was removed and the reaction was stopped with dimethylsulfoxide (100uL/well). The plates were placed on a shaker for 1min and the absorbance was determined on a plate reader at 570nm.
Tube formation assay
After the growth medium was replaced with serum-free RPMI-1640, supplemented with 10 unit/mL heparin and antibiotics, the HUVECs were incubated for 24 more hours. The cells were then trypsinized and resuspended in serum-free medium (1×10 5 cells/mL) in the presence of 50% (v/v) CM with or without of 5ug/mL K2. Before cells were plated, the wells of 96-well tissue culture plates were evenly coated with 50uL/well growth factor-reduced Matrigel (Becton Dickinson Labware, Bedford, MA, USA), which was allowed to solidify at 37 o C for 30min, according to the manufacturers instructions. The cell suspension was then plated (200uL/well) onto the surface of the Matrigel and incubated at 37 o C. The cells were photographed after 12h.
Stimulation of HUVEC and IL-6 measurement
HUVECs were stimulated with 50% (v/v) CM of K562 cells in the presence or absence of 10ug/ mL K2. After cells were removed by centrifugation, IL-6 concentrations in culture supernatants were determined by commercial enzyme-linked immunosorbent assay (R&D systems, Minneapolis, MN, USA) according to the manufacturers instructions. 
RESULTS
Down-regulation of endogenous VEGF expression by siRNA to VEGF
RT-PCR analysis was performed on total RNA from either siRNA-VEGF K562 cells or vector control K562 cells to assess the levels of VEGF mRNA expression. The results showed that the expression of VEGF mRNA was inhibited in K562 cells transfected with siRNA to VEGF, as compared to K562 cells transfected with vector alone, indicating that siRNA down-regulated the expression of endogenous VEGF (Fig. 1A) . Western blotting was also performed to detect the secreted VEGF by K562 cells. The blot showed that VEGF secretion of K562 cell was significantly decreased by transfection of siRNA targeting VEGF (Fig. 1B) .
Effects of CM of K562 cells on the proliferation of HUVECs
Transfection of siRNA to VEGF into K562 cells resulted in decreased VEGF expression and secretion, thereby a decreased capacity of the resultant CM to enhance the proliferation of HUVECs. To evaluate this effect, 50% (v/v) CM of K562 cells was added to the growth media of HUVEC. The proliferation of HUVECs induced by the CM from siRNA-VEGF K562 cells was decreased, compared with CM from vector control K562 cells (Fig. 2 ).
Effects on tube formation of HUVECs
HUVECs, plated on growth factor-reduced Matrigel, formed capillary-like structures in the absence of serum or exogenous growth factors. HUVECs were inhibited to form capillary-like structures in the presence of 5ug/mL K2. The ability of serum-starved HUVECs to form capillarylike structures was partially restored by CM of K562 cells (Fig. 3) . CM from siRNA-VEGF K562 cells were less effective than CM from vector control K562 cells, demonstrating that the activating effect was due to VEGF expression. HUVECs were cultured with 50% (v/v) CM of K562 cells in the presence (□) or absence (■) of 5 ug/mL K2 for 24h. The culture supernatant was centrifuged and IL-6 concentrations were determined by ELISA. Results represent the mean±SD (n=3). 
Effects of VEGF and K2 on IL-6 secretion by HUVECs
K562 cell-derived VEGF induced a time-dependent increase in IL-6 secretion by HUVECs (data not shown), implying there are paracrine interactions between myeloma and endothelial cells. CM from siRNA transfected K562 cells showed diminished IL-6 expression, indicating that IL-6 production by HUVECs was crossly related to exogenous VEGF concentrations ( Fig. 4) . IL-6 secretion was also inhibited in the presence of 10ug/mL K2.
DISCUSSION
Since Perez-Atayde et al. reported that bone marrow biopsies from children with acute lymphoblastic leukemia showed significantly higher microvessel densities than control specimens, 12) a number of investigators have indicated that leukemia cells induce angiogenesis in the bone marrow and that leukemia might be angiogenesis-dependent. 13, 14) VEGF, originally cloned from a human leukemia cell line HL60, has been found in many hematologic malignancies. An increased VEGF level has also been shown to be a predictor of unfavorable outcome in acute myeloid leukemia patients. 15) In an animal model using xenotransplanted human leukemia and lymphoma cell lines, a strong correlation was observed between the amount of VEGF produced in vitro by cultured cells and the efficiency of tumor engraftment. 16) VEGF is also expressed and secreted by myeloma cell lines and plasma cells isolated from bone marrow of patients with multiple myeloma. 9) In addition, circulating levels of VEGF have been shown to correlate with overall survival and event-free survival in non-Hodgkins lymphomas, and with progression-free survival in chronic lymphocytic leukemia. 17, 18) It has recently been demonstrated that down-regulation of VEGF in leukemia cells resulted in inhibition of tumor angiogenesis and tumor growth. Introduction of antisense VEGF into K562 cells resulted in the decrease of cell proliferation and migration. 19) It is well known that the introduction of siRNA into a mammalian cell triggers the degradation of the endogenous mRNA to which the siRNA hybridizes. 20) This mechanism is highly sequencespecific and allows to turn off the expression of a target protein. Previously, it was reported that a siRNA to VEGF successfully inhibited the secretion and expression of VEGF in PC-3, human prostate carcinoma cells, leading to the potent suppression of tumor growth in its xenograft model. 21) In this report, we evaluated the effect of siRNA targeting VEGF in K562 leukemia cells on tumor angiogenesis. The proliferation of HUVECs induced by the CM from siRNA-VEGF K562 cells was decreased, compared with CM from vector control K562 cells (Fig. 2) . The tube formation assay also indicated that siRNA to VEGF decreased the expression of VEGF in K562 cells (Fig. 3 ). Nevertheless, it was not sufficient to block angiogenesis by down-regulation of leukemia-derived VEGF with siRNA, indicating other angiogenic factors were also secreted by leukemia cells. The angiogenesis of HUVECs was significantly inhibited by combination with K2. Accumulating data suggest the existence of a paracrine loop between leukemia cells and endothelial cells that plays a significant role in supporting further growth of both cell populations. In this paracrine loop, VEGF secreted by leukemia cells may stimulate endothelial cell proliferation and promote them to secret more hematopoietic growth factors, such as IL-6, which in turn enhance further leukemia growth. 22) IL-6, a multifunctional cytokine, is produced by a number of cells and plays a role in the defense mechanism of a host. 23) Higher serum IL-6 levels were reported in patients with multiple myeloma, renal cell carcinoma, and ovarian cancer, compared with normal subjects. [24] [25] [26] Serum IL-6 level was recently reported to correlate with the disease status of gastric carcinoma and was demonstrated to decrease after tumor resection and increase when gastric carcinoma recurred. 27) It was also shown that the treatment of IL-6 resulted in a significant induction of VEGF mRNA in various cell lines including human epidermoid carcinoma cell line, rat skeletal muscle myoblast, and glioma cells. 28) Significant correlation between serum IL-6 and VEGF levels have been reported in a variety of advanced cancers. We here showed that VEGF, secreted in leukemia CM, promoted the production of IL-6 by HUVEC and the produced IL-6 level was decreased by adding K2 into growth media of HUVEC ( Fig. 4) . Since IL-6 may stimulate endothelial cell proliferation by enhancing VEGF production, the decreased level of IL-6, caused by K2, seems to be crossly related to the decreased proliferation of HUVEC. Numerous antiangiogenic agents are currently in clinical trials. Monotherapies in these assays have been disappointing, and several companies have abandoned drugs targeting VEGF or its receptors. 29) Since resistance could be responsible for the failures of these promising agents to consistently curtail human tumor growth, combinational therapies are required for elimination of tumor. 30, 31) For example, the joining of the antiangiogenic protein endostatin with an antisense strategy against the epidermal growth factor receptor (expressed on a fraction of human tumor cells) has been shown to produce synergistic inhibitory effects on tumor growth. 32) In this study, we show that the combination of si-RNA targeting VEGF and K2 can significantly inhibit tumor angiogenesis. In vivo transfection of siRNA targeting VEGF should be studied further to define the more effective set of treatment to tumor growth. 
